MapLight Therapeutics, Inc.: updates and filings

MPLTNASDAQHealthcare · Pharmaceutical Preparations

Price

$5.94

November 20, 2026Market cap $315M

What Ploutos Investor adds for MapLight Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 26, 2026 latest annualNov 16, 2026 latest quarterly
  • Nov 17, 2026Filing
    FormEFFECT
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Material agreement entered
    Form8-K
  • Nov 16, 2026Shelf registration for future offerings
    FormS-3
  • Nov 16, 2026Filing
    FormPOS AM
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 16, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Sep 23, 2026Filing
    FormEFFECT
  • Sep 18, 2026Filing (amendment)
    FormS-1/A
  • Sep 9, 2026Filing
    FormS-1
  • Aug 20, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 18, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 13, 2026Material agreement entered, results of operations, unregistered sale of shares, Regulation FD disclosure
    Form8-K
  • Aug 3, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 31, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 27, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jul 15, 2026Filing (amendment)
    Form144/A
  • Jun 24, 2026Shareholder vote
    Form8-K
  • Jun 22, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jun 18, 2026Officer or director change
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 14, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 14, 2026Results of operations, Regulation FD disclosure
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 8, 2019.

The full analysis

What do MapLight Therapeutics's filings show?

The filings are where every one of MapLight Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.